(MedPage Today) — Two insulin-dependent adolescents with type 1 diabetes and obesity had metabolic improvements after starting a low-dose GLP-1 agent, a case series showed.
One year after adding injectable semaglutide (Ozempic, Wegovy) to lifestyle…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
